

Single Agent Activity in Multiple Myeloma

Supplemental Table 1 Single Agents Investigated for the Treatment of Multiple Myeloma Found via Literature Search

1. 2-Chlorodeoxyadenosine (2CDA)³⁴
2. AB-100³⁵
3. Aclarubicin³⁶⁻³⁹
4. Acronine⁴⁰
5. All-trans retinoic acid (ATRA)⁵⁰
6. Amsacrine⁴¹
7. Anti-B4-bR⁴²
8. ARRY-520⁴³
9. Arsenic trioxide⁴⁴⁻⁴⁷
10. Atacicept⁴⁸
11. Atiprimod⁴⁹
12. AU922⁵¹
13. AVE1642⁵²
14. BB-10901⁵³
15. Belinostat (PXD101)⁵⁴
16. Bendamustine¹⁸
17. Bevacizumab⁵⁵
18. BIBF 1120⁵⁶
19. Bisantrene⁵⁷
20. Bleomycin⁵⁸
21. Bortezomib^{2,9,59-62}
22. Bryostatins 1⁶³
23. BT062^{64,65}
24. Carboplatin^{30,31}
25. Carfilzomib^{6,66-72}
26. CCNU⁷³
27. Cetuximab⁷⁴
28. Chlorozotocin^{75,76}
29. Circulated permuted trail (CPT)⁷⁷
30. Clarithromycin⁷⁸⁻⁸⁰
31. CLB IL6/8⁸¹
32. Clofarabine⁸²
33. Cyclophosphamide^{10,83-86}
34. Curcumin⁸⁷
35. Dacetuzumab⁸⁸
36. Daratumumab⁸⁹
37. Dasatinib⁹⁰
38. Denosumab⁹¹
39. Dexamethasone^{4,92-96}
40. Diaziquone⁹⁷
41. Didemnin⁹⁸
42. Dinaciclib⁹⁹
43. Docetaxel¹⁰⁰
44. Dovitinib^{101,102}
45. Doxorubicin/Adriamycin^{12,58,103}
46. Elotuzomab¹⁰⁴
47. ENMD 2076¹⁰⁵
48. Enzastaurin (data not published)
49. Epirubicin¹⁰⁶
50. Etoposide³³
51. Everolimus¹⁰⁷
52. Figitumumab¹⁰⁸
53. Flavoperidol^{109,110}
54. Fludarabine¹¹¹
55. Fluphenazine HCl¹¹²
56. Fotemustine^{15,113}
57. Gemcitabine^{114,115}
58. Givinostat¹¹⁶
59. GSK2110183¹¹⁷
60. Hydroxyurea¹¹⁸
61. Idarubicin²²⁻²⁵
62. IL-1Ra¹⁹
63. Imatinib¹²⁰
64. Imexon¹²¹
65. Interferon^{16,122-124}
66. Interleukin 12¹²⁵
67. IPH2101^{126,127}
68. IPI-504¹²⁸
69. L-asparaginase^{129,130}

Supplemental Table 1 Continued

70. Lenalidomide^{5,131-135}
71. Lorvotuzumab mertansine¹³⁶
72. Lucatumumab¹³⁷
73. Marizomib^{138,139}
74. Masitinib¹⁴⁰
75. MDX-1097¹⁴¹
76. Melphalan^{3,142-144}
77. Menogaryl^{145,146}
78. Meta sacrolysin³⁵
79. Methoxyestradiol¹⁴⁷
80. MFGR1877S¹⁴⁸
81. Methylglyoxalbisguanylylhydrazone (MGBG)¹⁴⁹
82. Milatuzumab¹⁵⁰
83. Mitomycin C³⁵
84. Mitoxantrone^{151,152}
85. MLN4924¹⁵³
86. MLN9708¹⁵⁴⁻¹⁵⁶
87. Mycophenolate mofetil¹⁵⁷
88. NSC 1026³⁵
89. NSC-752¹⁵⁸
90. Paclitaxel^{17,158}
91. Panobinostat^{160,161}
92. Pazopanib¹⁶²
93. Pentostatin¹⁶³
94. Perifosine¹⁶⁴
95. Piperazinedione¹⁶⁵
96. Plitidepsin¹⁶⁶
97. PM00104²²⁵
98. Pomalidomide^{8,167-170}
99. Prednimustine¹⁷¹
100. Prednisone^{11,172-175}
101. Pyrazofurin¹⁷⁶
102. Rituximab^{177,178}
103. Romidepsin¹⁷⁹
104. Rocilinostat¹⁸⁰
105. SAR650984¹⁴
106. SCIO-469¹⁸¹
107. Selumetinib¹⁸²
108. Semaxanib¹⁸³
109. SF1126¹⁸⁴
110. Sorafenib¹⁸⁵
111. SNS-032¹⁸⁶
112. Sunitinib¹⁸⁷
113. Tamoxifen¹⁸⁸
114. Tanespimycin¹⁸⁹
115. TBL 12¹⁹⁰
116. Temsirolimus¹⁹¹
117. Teniposide¹⁹
118. Thalidomide^{7,192-215}
119. Tipifarnib²¹⁶
120. Tivantinib²¹⁷
121. Topotecan²¹⁸
122. Troxacitabine²¹⁹
123. Urethane²²⁰
124. Vatalanib²²¹
125. Vandetanib²²²
126. Vincristine²⁷
127. Vindesine^{173,223}
128. Vinorelbine²²⁴
129. Vorinostat²⁶

Supplemental References

34. Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. *Blood* 1992; 80:1626.
35. Bergsagel DE. Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcosyls, and meta-sarcosyls, in the treatment of multiple myeloma. *Cancer Chemother Rep* 1962; 16:261-6.
36. Gockerman JP, Silberman H, Bartolucci AA. Phase II evaluation of aclaurubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. *Cancer Treat Rep* 1987; 71:773-4.
37. Karanes C, Crowley J, Sawkar L, et al. Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study. *Invest New Drugs* 1990; 8:101-4.
38. Sezaki T, Adachi T, Ishii H, Asano K, Takahashi I, Kimura I. Aclaurubicin in the treatment of multiple myeloma. *Jpn J Clin Oncol* 1984; 14:353-8.
39. Adachi T, Sezaki T, Ishii H, et al. Clinical responses and side effects of aclaurubicin (ACR) in the treatment of multiple myeloma [in Japanese]. *Gan To Kagaku Ryoho* 1983; 10:1653-8.
40. Scarffe JH, Beaumont AR, Crowther D. Phase I-II evaluation of acronine in patients with multiple myeloma. *Cancer Treat Rep* 1983; 67:93-4.
41. Greipp PR, Coleman M, Anderson K, McIntyre OR. Phase II trial of amsacrine in patients with multiple myeloma. *Med Pediatr Oncol* 1989; 17:76-8.
42. Grossbard ML, Fidas P, Kinsella J, et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. *Br J Haematol* 1998; 102:509-15.
43. Shah JJ, Zonder J, Cohen A, et al. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 449.
44. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. *Br J Haematol* 2004; 125:470-6.
45. Rousselot P, Larghero J, Arnulf B, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. *Leukemia* 2004; 18:1518-21.
46. Sanaat Z, Rezazadeh M, Gharamaleki JV, Ziae JE, Esfahani A. Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. *Acta Med Iran* 2011; 49:504-8.
47. Munshi NC. Arsenic trioxide: an emerging therapy for multiple myeloma. *Oncologist* 2001; 6(suppl 2):17-21.
48. Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. *Br J Cancer* 2009; 101:1051-8.
49. Wang M, Talpaz M, Jagannath S, et al. A phase I, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM). *Blood (ASH Annu Meet Abstr)* 2005; 106:abstract 111.
50. Koskela K, Pelliniemi TT, Pulkki K, Remes K. Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial. *Leuk Lymphom* 2004; 45:749-54.
51. Seggewiss-Bernhardt R, Bargou R, Goh YT, et al. Phase I/II study of AU922 alone or with bortezomib, in patients with relapsed or refractory multiple myeloma. *EHA Annu Meet Abstr* 2012; Abstract 0843.
52. Moreau P, Cavallo F, Leleu X, et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single-agent and in combination with bortezomib in patients with relapsed multiple myeloma. *Leukemia* 2011; 25:872-4.
53. Chanan-Khan AA, Jagannath S, Munshi NC, et al. Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2007; 110:abstract 1174.
54. Sullivan D, Singhal S, Schuster M, et al. A phase II study of PXD101 in advanced multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2006; 108:abstract 3583.
55. Somlo G, Lashkari A, Bellamy W, et al. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. *Br J Haematol* 2011; 154:533-5.
56. Kropff M, Kienast J, Bisping G, et al. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. *Anticancer Res* 2009; 29:4233-8.
57. Durie BG, Crowley J, Coltman CA Jr, et al. Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study. *Invest New Drugs* 1991; 9:329-31.
58. Bennett JM, Silber R, Ezdinli E, et al. Phase II study of Adriamycin and bleomycin in patients with multiple myeloma. *Cancer Treat Rep* 1978; 62:1367-9.
59. Min CK, Lee MJ, Eom KS, et al. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. *Jpn J Clin Oncol* 2007; 37:961-8.
60. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* 2003; 348:2609-17.
61. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. *Br J Haematol* 2004; 127:165-72.
62. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. *J Clin Oncol* 2009; 27:3518-25.
63. Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM. Phase II study of Bryostatins 1 in patients with relapsed multiple myeloma. *Invest New Drugs* 2001; 19:245-7.
64. Jagannath S, Chanan-Khan A, Heffner LT, et al. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 305.
65. Chanan-Khan AA, Jagannath S, Heffner LT, et al. Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 1862.
66. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood* 2012; 120:2817-25.
67. Lendvai N, Landau H, Lesokhin A, et al. Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 947.
68. Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). *ASCO Annu Meet Abstr* 2009; 27(suppl 15):abstract 8504.
69. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. *Blood* 2012; 119:5661-70.
70. Badros AZ, Vij R, Martin T, et al. Phase I study of carfilzomib in patients (pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiency. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 3877.
71. O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. *Clin Cancer Res* 2009; 15:7085-91.
72. Alsina M, Trudel S, Furman RR, et al. A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. *Clin Cancer Res* 2012; 18:4830-40.
73. Mass RE, MacKenzie M, Irwin LE. High-dose cyclophosphamide vs CCNU treatment of melphalan resistant myeloma. *Proc Am Assoc Cancer Res and ASCO* 1976; 250:abstract C55.
74. von Tresckow B, Boll B, Eichenauer DA, et al. A phase II clinical trial of the anti-EGFR Antibody cetuximab in patients with refractory or relapsed multiple myeloma: final results. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 3965.
75. Forman WB, Cohen HJ, Bartolucci AA, Manning G. Phase II evaluation of chlorzotocin in refractory multiple myeloma. *Cancer Treat Rep* 1984; 68:1409-10.
76. Cornell CJ Jr, Pajak TF, McIntyre OR. Chlorzotocin: phase II evaluation in patients with myeloma. *Cancer Treat Rep* 1984; 68:685-6.
77. Chen W, Qiu LG, Hou J, et al. Phase Ib study of recombinant circularly permuted trail (CPT) in relapsed or refractory multiple myeloma patients. *Blood (ASH Annu Meet Abstr)* 2012; 120:1857.
78. Stewart AK, Trudel S, Al-Berouti BM, Sutton DM, Meharchand J. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. *Blood* 1999; 93:abstract 4441.
79. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carotenuto M, Carella AM. Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report. *Haematologica* 2002; 87:658-9.
80. Moreau P, Huynh A, Facon T, et al. Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Francais du Myelome (IFM). *Leukemia* 1999; 13:490-1.
81. van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. *Br J Haematol* 1998; 102:783-90.
82. Uy GL, Tomasson MH, Ruddell A, DiPersio JF, Vij R. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma. *Haematologica* 2006; 91:1581-2.
83. Ailawadhi S, Keng M, Thara E, et al. High-dose cyclophosphamide: an effective non-transplant salvage option in relapsed/refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 4947.
84. Malhotra B, Porter DL, Stadtmauer EA, Schuster SJ, Vogl DT. Continuous infusion cyclophosphamide as salvage therapy for relapsed or refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 4942.
85. Bergsagel DE, Cowan DH, Hasselback R. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. *Can Med Assoc J* 1972; 107:851-5.
86. Korst DR, Clifford GO, Fowler WM, Louis J, Will J, Wilson HE. Multiple Myeloma. II. Analysis of Cyclophosphamide Therapy in 165 Patients. *JAMA* 1964; 189:758-62.
87. Vadhan-Raj S, Weber DM, Wang M, et al. Curcumin downregulates NF- κ B and related genes in patients with multiple myeloma: results of a phase I/II study. *Blood (ASH Annu Meet Abstr)* 2007; 110:abstract 1177.
88. Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. *Haematologica* 2010; 95:845-8.
89. Lokhorst H, Plesner T, Gimsing P, Nahi H, Lisby S, Richardson P. Daratumumab, A CD38 monoclonal antibody study in advanced multiple myeloma—an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study. *EHA Ann Meet Abstr* 2013:abstract S576.

Single Agent Activity in Multiple Myeloma

90. Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. *Leuk Lymphoma* 2009; 50:137-40.
91. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. *Am J Hematol* 2009; 84:650-6.
92. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2005; 352:2487-98.
93. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. *Ann Intern Med* 1986; 105:8-11.
94. Friedenberg WR, Kyle RA, Knosp WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. *Am J Hematol* 1991; 36:171-5.
95. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. *Blood* 1992; 80:887-90.
96. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. *Blood* 2008; 112:4445-51.
97. Stuckey WJ, Crowley J, Baker LH, et al. Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study. *Cancer Treat Rep* 1987; 71:1095-6.
98. Weiss RB, Peterson BL, Allen SL, Browning SM, Duggan DB, Schiffer CA. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. *Invest New Drugs* 1994; 12:41-3.
99. Kumar SK, LaPlant BR, Chng WJ, et al. Phase 1/2 trial of a novel CDK Inhibitor dinaciclib (SCH727965) in patients with relapsed multiple myeloma demonstrates encouraging single-agent activity. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 76.
100. Friedenberg WR, Graham D, Greipp P, Blood E, Winston RD. The treatment of multiple myeloma with docetaxel (an ECOG study). *Leuk Res* 2003; 27:751-4.
101. Lonial S, Alsina M, Anderson KC, et al. Phase I trial of chiral-258 in multiple myeloma. *ASCO Meet Abstr* 2006; 24(suppl 18):abstract 17502.
102. Scheid C, Reece D, Beksac M, et al. A phase 2 multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 4055.
103. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of Adriamycin in human neoplasia. *Cancer* 1973; 32:1-8.
104. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. *Blood* 2012; 120:552-9.
105. Farag S, Zhang S, Suvannasankha A, et al. Clinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma: interim phase I trial results. *Blood (ASH Annu Meet Abstr)* 2010; 116:abstract 1957.
106. Case DC Jr, Ervin TJ, Gams R, Sonneborn HL, Paul SD, Oldham FB. Phase I-II study of epirubicin in multiple myeloma. *Cancer Res* 1988; 48:6246-8.
107. Guenther A, Baumann P, Burger R, Klapper W, Schmidmaier R, Gramatzki M. Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study. *ASCO Meet Abstr* 2010; 28(suppl 15):abstract 8137.
108. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. *J Clin Oncol* 2008; 26:3196-203.
109. Dispenzieri A, Gertz MA, Lacy MQ, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. *Haematologica* 2006; 91:390-3.
110. Hofmeister CC, Bowers MA, Lee S, et al. Phase I trial of flavopiridol in relapsed multiple myeloma: brief response in t(4;14) with significant neutropenia. *Blood (ASH Annu Meet Abstr)* 2010; 116:abstract 1933.
111. Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. *Invest New Drugs* 1990; 8:199-200.
112. Stadtmayer EA, Siegel D, Vogl DT, et al. A Phase 1 trial of fluphenazine HCl (Fz), a serotonin antagonist, in relapsed and refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2008; 112:abstract 5188.
113. Dumontet C, Jaubert J, Sebban C, et al. Clinical and pharmacokinetic phase II study of fometustine in refractory and relapsing multiple myeloma patients. *Ann Oncol* 2003; 14:615-22.
114. Offidani M, Mele A, Corvatta L, et al. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma. *Leuk Lymphoma* 2002; 43:1273-9.
115. Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B. The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. *Invest New Drugs* 2002; 20:117-21.
116. Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. *Ann Hematol* 2010; 89:185-90.
117. Spencer A, Yoon S-S, Harrison SJ, et al. Novel AKT inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Preliminary results from a phase I first-time-in-human study. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 1856.
118. Davis P. Phase II studies of hydroxyurea (Nsc-32065) in adults: multiple myeloma and lymphoma. *Cancer Chemother Rep* 1964; 40:51-2.
119. Lust JA, Lacy MQ, Zeldenrust SR, et al. Long term follow-up of IL-1 receptor antagonist and dexamethasone phase II clinical trial in patients with smoldering/indolent myeloma shows improved survival in responsive patients: implications for targeting interleukin-1 induced il-6 production and the myeloma proliferative component. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 2945.
120. Dispenzieri A, Gertz MA, Lacy MQ, et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. *Leuk Lymphoma* 2006; 47:39-42.
121. Moehler TM, Golenkov A, Ludwig H, et al. Imexon (AOP 99.0001) for treatment of relapsed or refractory multiple myeloma: a phase I/II study. *Blood (ASH Annu Meet Abstr)* 2008; 112:abstract 5195.
122. Ludwig H, Cortelezzi A, Scheithauer W, et al. Recombinant interferon alpha-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. *Eur J Cancer Clin Oncol* 1986; 22:1111-6.
123. Quesada JR, Alexanian R, Hawkins M, et al. Treatment of multiple myeloma with recombinant alpha-interferon. *Blood* 1986; 67:275-8.
124. Costanzi JJ, Cooper MR, Scarffe JH, et al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. *J Clin Oncol* 1985; 3:654-9.
125. Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. *Leuk Res* 2009; 33:1485-9.
126. Benson DM Jr, Bakan CE, Padmanaban S, et al. IPH2101, a novel anti-inhibitory KIR monoclonal antibody for multiple myeloma: interim phase 1 Trial results and correlative biologic and safety data. *Blood (ASH Annu Meet Abstr)* 2010; 116:abstract 1966.
127. Korde N, Trepel J, Carlsten M, et al. A phase II trial of IPH2101 (anti-KIR mAb) in smoldering multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 2944.
128. Siegel D, Jagannath S, Vesole DH, et al. A phase 1 study of IPI-504 (retaspamycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. *Leuk Lymphoma* 2011; 52:2308-15.
129. Agrawal NR, Bukowski RM, Rybicki LA, Kurtzberg J, Cohen LJ, Hussein MA. A phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. *Cancer* 2003; 98:94-9.
130. Hussein MA, Kurtzberg J, Snyder J, et al. PEG-L-asparaginase (PL-A) in advanced multiple myeloma (MM): clinical results. *ASCO Annu Meet Abstr* 1997; 16:abstract 115.
131. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. *Leukemia* 2009; 23:605-7.
132. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. *Blood* 2009; 114:772-8.
133. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. *Blood* 2006; 108:3458-64.
134. Baz R, Patel M, Finley-Oliver E, et al. Single-agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. *Leuk Lymphoma* 2010; 51:1015-9.
135. Buadi F, Lacy M, Dispenzieri A, et al. Single-agent lenalidomide for newly diagnosed multiple myeloma with on-demand dexamethasone: A phase II trial. *ASCO Meet Abstr* 2011; 29(suppl):8080.
136. Chanan-Khan A, Wolf JL, Garcia J, et al. Efficacy analysis from phase I Study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated cd56-positive multiple myeloma - a preliminary efficacy analysis. *Blood (ASH Annu Meet Abstr)* 2010; 116:abstract 1962.
137. Bensinger W, Jagannath S, Becker PS, et al. A phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2006; 108:abstract 3575.
138. Richardson P, Hofmeister C, Jakubowiak A, et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 431.
139. Richardson PG, Spencer A, Cannell P, et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 302.
140. Arnulf B, Ghez D, Leblond V, et al. FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2007; 110:abstract 413.
141. Spencer A, Walker P, Asvadi P, et al. A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. *ASCO Meet Abstr* 2010; 28(suppl 15):abstract 8143.
142. Ahre A, Bjorkholm M, Mellstedt H, et al. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. *Eur J Cancer Clin Oncol* 1983; 19:499-506.
143. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. *JAMA* 1969; 208:1680-5.
144. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. *Blood* 1968; 31:1-10.

145. Cruz JM, Case LD, Dalton HB, et al. Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University. *Invest New Drugs* 1992; 10:35-7.
146. Kucuk O, Kilton L, Wade JL, Blough R, Benson AB 3rd, Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia. *Am J Clin Oncol* 2000; 23:379-83.
147. Rajkumar SV, Richardson PG, Lacy MQ, et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. *Clin Cancer Res* 2007; 13:6162-7.
148. Trudel S, Bergsagel PL, Singhal S, et al. A phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with relapsed or refractory T(4;14)-positive multiple myeloma. *ASH Annu Meet Abstr* 2012.
149. Winter JN, Ritch PS, Rosen ST, et al. Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study. *Cancer Invest* 1990; 8:143-6.
150. Kaufman JL, Niesvizky R, Stadmauer EA, et al. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. *ASCO Meet Abstr* 2009; 27(suppl 15):abstract 8593.
151. Esseesse I, Bartolucci AA, Gams RA, et al. Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial. *Cancer Treat Rep* 1986; 70:669-70.
152. Alberts DS, Balcerzak SP, Bonnet JD, Stephens RL. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. *Cancer Treat Rep* 1985; 69:1321-3.
153. Shah JJ, Harvey RD, O'Connor OA, et al. Phase I dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and/or refractory multiple myeloma or lymphoma. *Blood (ASH Annu Meet Abstr)* 2010; 116:abstract 2801.
154. Kumar S, Bensinger W, Reeder CB, et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study. *ASCO Meet Abstr* 2012; 30(suppl 15):abstract 8034.
155. Richardson PG, Baz R, Wang L, et al. Investigational AGENT MLN9708, an oral proteasome inhibitor, in patients (pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase I dose-escalation study. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 301.
156. Lonial S, Baz RC, Wang M, et al. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). *ASCO Meet Abstr* 2012; 30(suppl 15):abstract 8017.
157. Takebe N, Cheng X, Wu S, et al. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (CellCept) in advanced multiple myeloma patients. *Clin Cancer Res* 2004; 10:8301-8.
158. Edelstein MB, Crowley JJ, Valerioti FA, et al. A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study. *Invest New Drugs* 1990; 8(suppl 1):S83-6.
159. Dimopoulos MA, Arbutck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (Taxol). *Ann Oncol* 1994; 5:757-9.
160. Wolf JL, Siegel D, Matous J, et al. A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma. *Blood (ASH Annu Meet Abstr)* 2008; 112:abstract 2774.
161. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. *Blood (ASH Annu Meet Abstr)* 2008; 112:abstract 958.
162. Prince HM, Honemann D, Spencer A, et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). *Blood* 2009; 113:4819-20.
163. Grever MR, Crowley J, Salmon S, et al. Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study. *J Natl Cancer Inst* 1990; 82:1778-9.
164. Richardson P, Lonial S, Jakubowiak A, et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. *Blood (ASH Annu Meet Abstr)* 2007; 110:abstract 1164.
165. Jones SE, Tucker WG, Haut A, et al. Phase II trial of piperazineidone in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study. *Cancer Treat Rep* 1977; 61:1617-21.
166. Mateos MV, Cibeira MT, Richardson PG, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. *Clin Cancer Res* 2010; 16:3260-9.
167. Streeley MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. *Br J Haematol* 2008; 141:41-51.
168. Richardson PG, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. *Blood (ASH Annu Meet Abstr)* 2010; 116:abstract 864.
169. Streeley M, Stewart O, Gyertson K, Kazmi MA, Schey S. Pomalidomide monotherapy for relapsed myeloma is associated with excellent responses and prolonged progression free and overall survival. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 3878.
170. Richardson PG, Siegel DS, Vij R, et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 634.
171. Tirelli U, Sorio R, Magri MD, et al. Prednisone in elderly patients with multiple myeloma: a phase II study. *Cancer Treat Rep* 1986; 70:537-8.
172. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. *Cancer Chemother Rep* 1962; 16:257-9.
173. Alexanian R, Yap BS, Bodey GP. Prednisone pulse therapy for refractory myeloma. *Blood* 1983; 62:572-7.
174. Salmon SE, Shaddock RK, Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. *Cancer Chemother Rep* 1967; 51:179-87.
175. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. *Leukemia* 1995; 9:2115-8.
176. Lake-Lewin D, Myers J, Lee BJ, Young CW. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy. *Cancer Treat Rep* 1979; 63:1403-4.
177. Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma. *Leukemia* 2007; 21:835-6.
178. Zojer N, Kirchbacher K, Vesely M, Hubl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. *Leuk Lymphoma* 2006; 47:1103-9.
179. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. *Cancer* 2011; 117:336-42.
180. Rajc N, Hari PN, Vogl DT, et al. Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 4061.
181. Siegel DS, Krishnan A, Lonial S, et al. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). *Blood (ASH Annu Meet Abstr)* 2006; 108:abstract 3580.
182. Holkova B, Badros AZ, Geller R, et al. A phase II study of the MEK 1/2 inhibitor AZD6244 (selumetinib, ARRY-142866) in relapsed or refractory multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 2931.
183. Zangari M, Anaisie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. *Clin Cancer Res* 2004; 10:88-95.
184. Lonial S, Harvey RD, Francis D, et al. Preliminary results of a phase I study of the pan-P13 kinase inhibitor SF1126 in patients with relapsed and refractory myeloma. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 3879.
185. Srkalic G, Hussein M, Bolejack V, Hoering A, Zonder J, Barlogie B. A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434). *ASCO Annu Meet Abstr* 2009; 27(suppl 15):e19517.
186. Tong WG, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. *J Clin Oncol* 2010; 28:3015-22.
187. Kumar S, Flynn PJ, Chng WJJ, et al. A phase II trial of sunitinib (SU11248) in multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2009; 114:abstract 4954.
188. Decaudin D, Etienne MC, De Cremoux P, et al. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma. *J Natl Cancer Inst* 2004; 96:636-7.
189. Richardson PG, Chanan-Khan AA, Alsina M, et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase I dose-escalation study. *Br J Haematol* 2010; 150:438-45.
190. Chari A, Mazumder A, Ditrilo L, Galitckey Z, Jagannath S. A phase II trial of TBL 12 Sea cucumber extract in patients with untreated asymptomatic myeloma. *Blood (ASH Annu Meet Abstr)* 2011; 118:abstract 3992.
191. Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. *Leuk Res* 2009; 33:1475-80.
192. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. *Leukemia* 2003; 17:775-9.
193. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide therapy of resistant or relapsed multiple myeloma patients. *Haematologica* 2001; 86:404-8.
194. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. *Br J Haematol* 2000; 109:89-96.
195. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the Intergroupe Francophone du Myelome (IFM). *Hematol J* 2002; 3:185-92.
196. Schey SA, Cavenagh J, Johnson R, Child JA, Oakerve H, Jones RW. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. *Leuk Res* 2003; 27:909-14.
197. Guglielmelli T, Capella S, Saglio G. Very low doses of thalidomide as single-agent in relapsed/refractory multiple myeloma. *Acta Haematol* 2006; 116:70-1.

Single Agent Activity in Multiple Myeloma

198. Detweiler-Short K, Hayman S, Gertz MA, et al. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. *Am J Hematol* 2010; 85:737-40.
199. Grosbois B, Duguet C. Thalidomide: the revival [in French]. *Rev Med Interne* 2001; 22:5-7.
200. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. *N Engl J Med* 1999; 341:1565-71.
201. Cibeira MT, Rosinol L, Ramiro L, Esteve J, Torrealbadell M, Blade J. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. *Eur J Haematol* 2006; 77:486-92.
202. Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. *Clin Cancer Res* 2002; 8:3377-82.
203. Waage A, Gimsing P, Juliussen G, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. *Br J Haematol* 2004; 125: 149-55.
204. Leleu X, Magro L, Fawaz A, Bauters F, Facon T, Yakoub-Agha I. Efficacy of a low dose of thalidomide in advanced multiple myeloma. *Blood* 2002; 100:1519-20.
205. Durie BG, Stepan DE. Efficacy of low dose thalidomide in multiple myeloma. *J Clin Oncol* 2000; 1:1-8.
206. Alexanian R, Weber D. Thalidomide for resistant and relapsing Myeloma. *Semin Hematol* 2000; 37(suppl 3):22-5.
207. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. *Blood* 2003; 102:69-77.
208. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. *Haematologica* 2002; 87:408-14.
209. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. *Blood* 2001; 98:492-4.
210. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. *Mayo Clin Proc* 2003; 78:34-9.
211. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. *Mayo Clin Proc* 2000; 75:897-901.
212. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. *J Clin Oncol* 2003; 21:16-9.
213. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. *Leukemia* 2001; 15:1274-6.
214. Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. *Eur J Haematol* 2004; 72:403-9.
215. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. *Mayo Clin Proc* 2004; 79:875-82.
216. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. *Blood* 2004; 103:3271-7.
217. Dorkhorn SJ, Zaman S, Thomas SK, et al. Phase II study of the CET inhibitor RQ 197 (tivantinib) in patients with relapsed multiple myeloma. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 2976.
218. Kraut EH, Crowley JJ, Wade JL, et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. *J Clin Oncol* 1998; 16:589-92.
219. Vose JM, Panwalkar A, Belanger R, et al. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. *Leuk Lymphoma* 2007; 48:39-45.
220. Holland JR, Hosley H, Scharlau C, et al. A controlled trial of urethane treatment in multiple myeloma. *Blood* 1966; 27:328-42.
221. Vij R, Anstas G, Mosley JC, et al. Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. *Leuk Lymphoma* 2010; 51:1577-9.
222. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. *Invest New Drugs* 2006; 24: 529-35.
223. Houwen B, Ockhuizen T, Marrink J, Nieweg HO. Vindesine therapy in melphalan-resistant multiple myeloma. *Eur J Cancer* 1981; 17:227-32.
224. Harousseau J, Dammacco F, San Miguel J. An alternative treatment for relapsed/resistant multiple myeloma (MM): vinorelbine (VRL), plus high-dose dexamethasone (DEX): two phase II studies. *Proc Am Soc Clin Oncol* 1999; 8: abstract 29a.
225. Ocio EM, De la Rubia J, Oriol-Rocafiguera A, et al. Phase II optimization, open-label clinical trial of Zalypsis (PM00104) in relapsed/refractory multiple myeloma patients. *Blood (ASH Annu Meet Abstr)* 2012; 120:abstract 4041.